A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

NCT05372419 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
90
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Eli Lilly and Company